[O6] Oral Session 6　Lung Cancer / Thoracic Cancer 1（Molecularly-targeted therapy EGFR, ALK）
【E】

[O6-4] A rP2 study comparing Nivo with CBDCA-PEM for EGFRm NSCLC acquired TKI-resistance not due to T790M (WJOG8515L)

^○Atsushi Nakamura¹, Hidetoshi Hayashi², Takehiro Uemura³, Shigeki Mitsuoka⁴, Kentaro Ito⁵, Junji Uchida ⁶, Yosuke Tamura⁷, Yasuo Iwamoto⁸, Masahide Oki⁹, Satoru Kitazono¹⁰, Yoshikazu Hasegawa¹¹, Akihito Kubo¹², Katsuhiko Naoki¹³, Satoshi Ikeda¹⁵, Kageaki Watanabe¹⁶, Yasutaka Chiba¹⁷, Kazuko Sakai¹⁸, Kazuto Nishio¹⁸, Nobuyuki Yamamoto¹⁸, Kazuhiko Nakagawa Kazuhiko Nakagawa² (1.Department of Pulmonary Medicine, Sendai Kousei Hospital, 2.Department of Medical Oncology, Kindai University Faculty of Medicine, 3.Nagoya City University Hospital, 4.Department of Clinical Oncology, Graduate School of Medicine, Osaka City University, 5.Respiratory Center, Matsusaka Municipal Hospital, 6.Department of Respiratory Medicine, Osaka General Medical Center, 7.Osaka Medical and Pharmaceutical University, 8.Hiroshima City Hiroshima Citizens Hospital, 9.Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, 10.Cancer Institute Hospital, Japanese Foundation for Cancer Research  , 11.Izumi City General Hospital, 12.Aichi Medical University School of Medicine, 13.Department of Respiratory Medicine, Kitasato University School of Medicine, 14.Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 15.Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 16.Clinical Research Center, Kindai University Hospital, 17.Department of Genome Biology, Kindai University Faculty of Medicine, 18.Internal Medicine III, Wakayama Medical University)